2nd annual diabetes and diabetic retinopathy (2011)


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

2nd annual diabetes and diabetic retinopathy (2011)

  1. 1. 2nd Annual Diabetes and Diabetic Retinopathy Identifying new therapeutic opportunities for diabetes and diabetic retinopathy 15th - 16th June 2011, Visiongain Conference Centre, London, UK BOOK NOW! Key Speakers Dr. Peter Adamson, Vice President and Head of Research Ophthiris, GlaxoSmithKline Dr. Richard Carr, Senior Director, Merck Sharp & Dohme Dr. Hans-Jürgen Wörle, Vice President, Therapeutic Area Head Metabolism, Boehringer Ingelheim Pharma GmbH & Co. KG Dr. Michael Mark, Vice president, Therapeutic Area CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG Dr. David H Solomon, President , Chief Executive Officer, Zealand pharma A/S Dr. Rob Jones, Senior Director, Medicinal Chemistry, Arena Pharmaceuticals David M. Kendall, Chief Scientific and Medical Officer, American Diabetes Association Dr. Araneo Barbara, Director of Complications Research, Juvenile Diabetes Research Foundation Dr. Ennio Ongini, Vice President Research, NicOx Dr. Selwyn Ho, Sr.Director, Marketing, Retina, Allergen EAME Professor. P.M. Dodson, M.D, FRCP, FRCOphth Consultant, Diabetes & Medical Ophthalmology, Birmingham Heartlands Hospital, Birmingham, UK Professor Sue Lightman, Professor of Clinical Ophthalmology and Consultant Ophthalmologist, Institute of Ophthalmology, University College London / Institute of Ophthalmology and Moorfields Eye Hospital Alireza Falahati-Nini, M.D, FACE President, Utah Endocrinology Associates Medical Director, St. Mark’s Hospital Diabetes Center Simon Taylor MA PhD FRCOphth, NIHR Clinical Lecturer in Ophthalmology, UCL Institute of Ophthalmology Driving the Industry Forward | www.futurepharmaus.comMedia Partners Organised By To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/diabetes
  2. 2. Conference Introduction 2nd Annual Diabetes and Diabetic Retinopathy 15th - 16th June 2011, London, UK Dear Colleague, Media Partners: iabetes is becoming an epidemic and is expected to reach $86.9 billion by 20251; D PharmiWeb.com is the leading industry-sponsored portal for world health organisation predicts that 4.4% of the world population will have the pharmaceutical sector. Supported by most of the leading diabetes by 2030. Of the 246 million people with diabetes about third have signs pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, of diabetic retinopathy3 and about third of these might have vision –threatening features, events listings and international jobs to industry professionals across Europe retinopathy defined as severe retinopathy or macular oedema4. and the US. esearch is constantly going on to develop a better understanding of physiologic R For further information please email: corporate@pharmiweb.com characteristics of type 1 and type 2. Recognition of the contribution of fasting and postprandial blood glucose levels to overall glycemia, new treatment approaches that focus on achieving tight glycemic control and other therapeutic options that BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY allow the practitioner to develop treatments tailored to meet the individual patient WORLD. It is based and located in Warsaw, Poland. needs are being addressed. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma isiongain’s 2nd Annual Diabetes and Diabetic Retinopathy conference is designed to V information and market to make it universally accessible and useful for scientific bring together the industry experts to discuss every aspect of drug development for and business processes. Its first step to fulfilling that mission was building the diabetes, from latest clinical development through to dealing with regulatory issues. BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet By attending this conference, you will: public relations, publication and marketing solutions. One of the mains goals of • ssess new developments in currently used treatments –Human insulins and A BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to analogues,DPP-IV inhibitors, Sulphonylurea and Biguanide, Alpha-Glucosidase global biotechnology, pharmaceutical and life science activities. Inhibitor, GLP-1 agonist, SGLT inhibitor etc For further information please visit: www.biotechnology-europe.com • ain insight about the future market trends in insulin, oral anti-diabetic and non G insulin injections Future Pharmaceuticals has forged powerful relationships Driving the Industry Forward | www.futurepharmaus.com • ind new treatments for diabetes F with key industry leaders to provide a platform for successful • vercome challenges in developing novel anti-diabetic therapies O brand recognition, and for senior decision-makers to have the means to procure and • valuate the latest clinical development for diabetic retinopathy E plan implementation strategies based on the topics covered. Positioned to be an • ffectively target glycaemia and blood pressure levels for prevention of E authoritative resource within top pharma companies as well as small, specialty, and retinopathy development and progression biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into • dvance role of lipid lowering therapy A a highly targeted and responsive audience, bridging the gap between the industries’ • nderstand the new medical treatments in diabetic retinopathy –ocular therapy U top issues and the solutions top-tier vendors can provide. For further information please visit: www.futurepharmaus.com (laser photocoagulation) • xplore emerging ophthalmic treatments –Glucocorticoids and the role of drug E delivery systems in the management of Diabetic Macular Edema and Anti-VEGF therapy InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is • xamine the challenges in regulating development & approval of drugs in E home to InPharmjobs.com, Pharmafile and Pharmafocus. Diabetes For further information please visit: www.In-Pharm.com I look forward to meeting you at the conference Best regards Glycosmedia is a free, non-promotional, editorially independent diabetes news service for healthcare professionals. Its function is to bring the latest diabetes news and information to those working in the field of diabetes, both in the clinic and in research. A free weekly e-mail newsletter is also available. Sonia Tomar For further information please visit: http://www.glycosmedia.com/ Conference Producer Who will be there? Sponsorship and exhibition opportunities Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, This event offers a unique opportunity to meet and do business with some Senior Directors, Directors, Clinicians, Principal Scientists, Principal of the key players in the pharmaceutical and biotech industries. If you have Investigators, Managers, Project/Team Leaders in: a service or product to promote, you can do so at this event by: • Diabetes & Obesity, Pre-Clinical and Clinical R&D • Retinal Diseases • Hosting a networking drinks reception • Ophthalmology, Visual Science and Vision Research • Taking an exhibition space at the conference • Endocrinology and Metabolic Diseases • Advertising in the delegate documentation pack • Cardiovascular and Gastrointestinal Diseases • Anti-Diabetic Agents & Advanced Diabetes Systems • Providing branded bags, pens, gifts, etc. • Drug Development If you would like more information on the range of sponsorship or • Monoclonal Antibodies • Molecular Neuroscience exhibition possibilities for visiongains 2md Annual Diabetes and Diabetic • New Products Global Marketing Retinopathy Conference, please contact us: • Business Development, Licensing & Partnership • Venture Capital Ronald Magali, +44 (0)20 7549 9934 • Regulatory Affairs ronald.magali@visiongainglobal.com 1 Visiongain, (2010). World Diabetes Market Analysis Report, 2010-2025.2 International Diabetes Federation .Diabetes atlas 2007.http://www.eatlas.idf.org3 Saaddine JB,Honeycutt AA,Narayan KM ,Zhang X,Klein R, Boyle JP .Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus:United States 2005-2050.Arch Opthalmol 2008;126:1740-47
  3. 3. Day 1 2nd Annual Diabetes and Diabetic Retinopathy Wednesday 15th June 2011 09:00 Registration and refreshments 13:40 GPR119 Agonists for the treatment of Type 2 Diabetes • Overview of GPR119 09:30 Opening address from the chair • Mechanism of glycemic control • Clinical status 09:40 Perspective on emerging treatments for diabetic Dr. Rob Jones retinal disease and the challenges for prevention Senior Director, Medicinal Chemistry and treatment Arena Pharmaceuticals • Overview on diabetes • JDRF view of clinical unmet need 14:20 DPP-4 Inhibitors updates - Reach out to adolescents and adults Dr. Richard Carr - Screening and prevention Senior Director - Sight-sparing treatment Merck Sharp & Dohme • JDRF view of gaps in research - Collaboration 15:00 Afternoon Refreshments - Diagnostics - Therapies 15:20 Treatment targets in diabetes: where do we stand - Policy and reimbursement following ACCORD? - Education • eview the history of studies in intensive glycemic control (from UGDP to R ACCORD) and discuss the impact of these interventions on microvascular Dr. Barbara A. Araneo complications in diabetes Scientific Program Director - Complications Therapies Juvenile Diabetes Research Foundation • iscuss the relative impact of early vs late intervention and its impact on D microvascular complications risk • utline the findings of more recently published studies of more intensive O 10:20 Finding new treatments for diabetes glycemic control (ACCORD, ADVANCE and VADT) as relates to retinal • DPP4- inhibitors complications of diabetes • SGLT-2 inhibitors • eview the risk-benefit of more intensive treatment strategies as relates R Dr. Michael Mark to diabetes intervention Vice president, Therapeutic Area Cardio Metabolic Disease •D iscuss current treatment targets for glucose, lipids and blood pressure Boehringer Ingelheim Pharma GmbH & Co. KG following completion of the ACCORD trial David M. Kendall, MD 11:00 Morning refreshments Chief Scientific and Medical Officer American Diabetes Association 11:20 Examine the challenges in regulating development & approval of drugs in diabetes 16:00 Review of current and emerging - DPP-4 Inhibitors • mplication of the new FDA CV guidance, can one still develop I and GLP-1 Analogs gluco-centric compounds? • eview of the Physiology of Incretins (GLP-1 and GIP) as well as R • hat is feasible size of a phase III program in the light of the W DPP-4 Inhibitors new requirements? • eview of current and emerging drugs from the GLP-1 and DPP-4 R • What patients should be included and at what stage of the CDP? Inhibitor classes Dr. Hans-Jürgen Wörle • eview of current evidence for “Beta-Cell Preservation” in animals R Vice President, Therapeutic Area Head Metabolism (and Humans?) C MED Clinical Development & Medical Affairs • eview of current evidence of positive effect of these two classes on R Boehringer Ingelheim Pharma GmbH & Co. KG cardiovascular health • eview of long-term data (5-year +) on sustainability of diabetes R 12:00 GLP-1 - new treatment paradigms in diabetes - The management with these two new classes Zealand Pharma Story • Potential Adverse effects and why? • Overview of GLP-1s Alireza Falahati-Nini, M.D., FACE • he discovery at Zealand of Lixisenatide and its commercialisation by T President, Utah Endocrinology Associates sanofi-aventis Medical Director, St. Mark’s Hospital Diabetes Center • New directions of GLP-1s in the treatment of diabetes and related obesity Dr. David H Solomon 16:40 Closing remarks from the chair President, Chief Executive Officer ZEALAND Pharma A/S 16:50 Networking drinks 12:40 Networking lunch Take your discussions further and build new relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
  4. 4. Day 2 2nd Annual Diabetes and Diabetic Retinopathy Thursday 16th June 201109:00 Registration and refreshments 12:40 Networking lunch09:30 Opening address from the chair Professor Sue Lightman 13:40 Emerging ophthalmic treatments Professor of Clinical Ophthalmology -Anti-VEGF therapy UCL/Institute of Ophthalmology and • Rationale for anti-VEGF agents in diabetic macular edema Moorfields Eye Hospital • Types of anti-VEGF agents in use09:40 Role of lipid lowering therapy in diabetes retinopathy • Results of the main clinical studies./ trials • ow do lipids influence eye disease? H • elationship of lipids and diabetic retinopathy R • Comparison with other treatment modalities • otential mechanisms of retinal damage by lipids P • Their use in clinical practise • reatment of retinopathy with lipid lowering drugs: T statins and fibrates Professor Sue Lightman • ARDS, FIELD, ACCORD-EYE Studies C Professor of Clinical Ophthalmology • onclusion C UCL/Institute of Ophthalmology and Moorfields Eye Hospital PROFESSOR. P.M. DODSON, MD, FRCP, FRCOphth Consultant, Diabetes & Medical Ophthalmology, Departments of Diabetes, Ophthalmology, & Heart of England Diabetic Retinopathy Screening Centre Birmingham Heartlands Hospital, Birmingham, UK 14:20 Emerging medical treatments - Ocular therapy • Advances in laser for proliferative disease10:20 Nitric oxide-donating glucocorticoids for effective • Advances in laser for diabetic macular oedema and safe treatment of diabetic macular edema • argeting nitric oxide (NO) for the treatment of eye diseases T • Where are we now? - results of the clinical trials • itric oxide and IOP lowering N • Role of vitreoretinal surgery • itric oxide and oxygen saturation of the retina and ONH N • otential of NO-donating glucocorticoids P Simon Taylor MA PhD FRCOphth Dr. Ennio Ongini NIHR Clinical Lecturer in Ophthalmology Vice President Research UCL Institute of Ophthalmology NicOx11:00 Morning refreshments 15:00 Afternoon refreshments11:20 Pazopanib eye drops in mouse models of diabetic eye disease 15:20 Systemic therapy in treatment of diabetic retinopathy • Pazopanib is a multi-spectral tryrosine kinase inhibitor • arget glycaemia and blood pressure levels of effective prevention of T • Pazopanib eye drops are in PhIIb development for neovascular AMD retinopathy development and progression • ill discuss efficacy of pazopanib in models of vascular leak and W retinal neovascularisation • fficiency of hypoglycaemic and blood pressure lowering agents E Dr. Peter Adamson Vice President and Head of Research Ophthiris GlaxoSmithKline 16:00 Pharmacological inhibition of diabetic retinopathy • ldose reductase inhibitors A12:00 Emerging ophthalmic therapies: Glucocorticoids and • nti-inflammatory methods A the role of drug delivery systems in the management of diabetic macular edema • rotein kinase C activation and its pharmacological inhibition in P • he pathophysiology of diabetic macular edema (DME) has a clear T vascular disease inflammatory component • lucocorticoids have been a key part of the armamentarium for the G management of DME, both in monotherapy and in combination with 16:40 Chair’s closing remarks other modalities • ifferences in the glucocorticoid molecular structure, routes of administration D and pharmacokinetic profiles may result in clinically relevant differences • n a long-term, chronic disease such as DME, Glucocorticoids in long I 16:50 End of conference duration drug delivery systems may play a role in reducing the burden of drug administration to patients, physicians and health care systems Dr. Selwyn Ho Sr. Director, Marketing, Retina Allergen EAME
  5. 5. Registration Form 2nd Annual Diabetes and Diabetic Retinopathy 15th - 16th June 2011, London, UK Angel Conf. code VG Pentonville Road 2nd Annual Diabetes and CiStandard Prices ty Diabetic Retinopathy Ro adConference only Fee: £1299 VAT: £259.80 Total: £1558.80 15th - 16th June 2011 Old StreetNumber of bookings: Total cost: Location: Visiongain Conference Centre Old Street Address: 230 City RoadPromotional Literature Distribution City Road LondonDistribution of your company’s promotional literature to all conference attendees EC1V 2TT UK Fee: £999 VAT: £199.80 Total: £1198.80Details How to bookForename: Surname: Email: conferences@visiongainglobal.com Web: http://www.visiongain.com/diabetes Job Title: Company: UK Office: Tel: +44(0) 20 7336 6100 Fax: +44(0) 20 7549 9932 Main Switchboard Number: Visiongain Ltd BSG HouseAddress: 226-236 City Road London EC1V 2QY UKCountry: Postcode: General information Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343Email: http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 Signature: 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340 Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain I confirm that I have read and agree to the terms and conditions of booking Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices.Methods of payment Substitutions/name changes or cancellations: There is a 50% liability on all bookings once Payment must be made in sterling made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice By Mail: Complete and return your signed registration form together with your cheque payable must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and By Fax: Complete and fax your signed registration form with your credit card details substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable.to +44 (0) 20 7549 9932 Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive By Bank Transfer: briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try Visiongain Ltd A/C: visiongain Ltd to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or Barclays Bank Sort Code: 20-71-64 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the Piccadilly Branch Account No: 6038 7118 cost of the registration, travel and expenses.48 Regent Street Swift Code: BARC GB22 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data London, W1B 5RA IBAN: GB80 BARC 20716460387118 Protection Act 1988. Your personal information contained in this form may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We Please debit my credit card: may also share your data with external companies offering complementary products or services. If you wish for your details to be amended, suppressed or not passed on to any external third party, please Access MasterCard Visa American Express send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from Card number: visiongain Ltd during the transitional period, whilst the changes are coming into effect. Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly Expiry Date: recommend you obtain). VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT Security number (last 3 digits on back of credit card): incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT.Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.Cardholder’s name: Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send News updates with your payment. You will receive speaker talks in PDFs two weeks after the event.Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660 www.visiongain.com/diabetes